Background: Anaphylaxis is classically mediated by allergen cross-linking of IgE bound to the a chain of FcεRI, the mast cell/basophil high affinity IgE receptor. Allergen cross-linking of the IgE/FcεRI complex activates these cells, inducing release of disease-causing mediators, cytokines, and enzymes. We previously demonstrated that IgE-mediated anaphylaxis could be safely prevented in wild-type BALB/c mice by rapid desensitization with anti-mouse FcεRIa mAb. Objective: This study sought to use humanized mice to extend these results to humans. Methods: We actively immunized huFcεRIa/F709 mice, which express human (hu) instead of mouse FcεRIa and a mutant IL-4 receptor that lacks inhibitory function. We passively immunized huFcεRIa mice, as well as human cord blood-reconstituted reNSGS mice, which are immune-deficient, produce mast cellstimulating human cytokines, and develop numerous human mast cells. For desensitization, we used anti-huFcεRIa mAbs that bind FcεRIa regardless of its association with IgE (noncompeting mAbs), and/or mAbs that compete with IgE for huFcεRIa binding (competing mAbs). Anaphylaxis was induced by intravenous injection of antigen or anti-huIgE mAb. Results: Anti-huFcεRIa mAb rapid desensitization was safer and more effective than allergen rapid desensitization and suppressed anaphylaxis more rapidly than omalizumab or ligelizumab. Rapid desensitization of na€ ıve, IgE-sensitized huFcεRIa mice and huFcεRIa/F709 mice that were egg-allergic with anti-FcεRIa mAbs safely removed >98% of IgE from peritoneal mast cells and completely suppressed IgE-mediated anaphylaxis. Rapid desensitization of reNSGS mice with anti-FcεRIa mAbs also safely removed 98% of mast cell IgE and prevented IgE-mediated anaphylaxis. Conclusions: Rapid desensitization with anti-FcεRIa mAbs may be a safe, effective, and practical way to prevent IgE-mediated anaphylaxis.